Trials / Conditions / Monoclonal Gammopathy

Monoclonal Gammopathy

11 registered clinical trials studyying Monoclonal Gammopathy — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Pre-malignant States to Hematologic Malignancies in Firefighters NCT06870760	Wake Forest University Health Sciences	—
Not Yet Recruiting	Multi-center Screening for Serum M Protein NCT06750965	Zhujiang Hospital	—
Not Yet Recruiting	Screening for Monoclonal Gammopathy in Individuals Undergoing Physical Examinations Using iMS-LC Assay Technol NCT06489613	Jian Li	—
Withdrawn	Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma NCT03591614	Case Comprehensive Cancer Center	EARLY_Phase 1
Recruiting	Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance NCT04614558	Columbia University	Phase 2
Completed	Frequency and Characteristics of Pruritus in Patients With Monoclonal Gammopathy NCT03832140	University Hospital, Brest	—
Active Not Recruiting	Rifaximin in Patients With Monoclonal Gammopathy NCT03820817	Emory University	Phase 1
Active Not Recruiting	Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multip NCT03236428	Dana-Farber Cancer Institute	Phase 2
Completed	A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early NCT02741999	Tufts Medical Center	—
Completed	Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy NCT01543100	Rennes University Hospital	N/A
Unknown	Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis NCT00173264	National Taiwan University Hospital	—